BioNTech (BNTX) director Susanne Schaffert files Form 3 ownership

Rhea-AI Filing Summary

BioNTech SE director Susanne Schaffert has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing lists her as a director and does not report any stock purchases, sales, or other share transactions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/26/2026 - 09:09 AM Accepted by SEC EDGAR 06/26/2026 - 09:08 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schaffert Susanne

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/26/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Humza Bokhari, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 for Susanne Schaffert show?

The Form 3 shows that Susanne Schaffert is a director of BioNTech SE and has filed an initial statement of beneficial ownership. The filing does not report any stock purchases, sales, or other share transactions in BioNTech shares.

Did Susanne Schaffert buy or sell BioNTech (BNTX) shares in this Form 3?

No, this Form 3 does not report any purchases or sales of BioNTech shares by Susanne Schaffert. It is an initial ownership statement with no listed transactions or changes in her position disclosed in the data provided.

What is the purpose of a Form 3 for BioNTech (BNTX) insiders?

Form 3 is used to report the initial beneficial ownership of company securities by directors, officers, and large shareholders. It establishes a baseline of their holdings when they become insiders, even when no specific stock transactions are disclosed.

What insider role does Susanne Schaffert hold at BioNTech (BNTX)?

The filing data identifies Susanne Schaffert as a director of BioNTech SE. As a director, she is considered an insider for reporting purposes and must file ownership reports such as Form 3 and any future transaction reports when required.

Does this BioNTech (BNTX) Form 3 include derivative securities activity?

No, the data for this Form 3 shows no derivative security transactions or holdings listed. The derivative summary is empty, and there are no exercises, conversions, or other derivative-related entries reported for Susanne Schaffert.